Results 151 to 160 of about 8,557 (171)

CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology

Immunotherapy, 2021
The drug infliximab has been a key milestone in the treatment of inflammatory conditions such as Crohn's disease, ulcerative colitis, rheumatoid arthritis and the seronegative spondyloarthritides. Biosimilar drugs followed the originator, further improving access and diversity of therapy choice.
Mai Ahmed, Giulia Bankov, Dan Casey, Martin Edward Perry   +3 more
openaire   +2 more sources

CT-P13 SC for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2021
Management of Rheumatoid Arthritis (RA) has improved following the implementation of early intensive treat to target recommendations and the availability of different biologicals. Most experience is with TNF blockers, but challenges remain in the efficacy/safety balance, immunogenicity, and long-term drug survival as well as availability and ...
openaire   +2 more sources

Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis

Journal of Clinical Gastroenterology, 2022
Background: We aimed to compare trough infliximab levels and the development of antidrug antibody (ADA) for 1 year between Crohn’s disease (CD) and ulcerative colitis (UC) patients who were biologic-naive, and to evaluate their impact on clinical outcomes.
Kim, Eun Soo, Kim, Sung Kook, Park, Dong Il, Kim, Hyo Jong, Lee, Yoo Jin, Koo, Ja Seol, Kim, Eun Sun, Yoon, Hyuk, Lee, Ji Hyun, Kim, Ji Won, Shin, Sung Jae, Kim, Hyung Wook, Kim, Hyun-Soo, Park, Young Sook, Kim, You Sun, Kim, Tae Oh, Lee, Jun, Choi, Chang Hwan, Han, Dong Soo, Chun, Jaeyoung, Kim, Hyun Soo   +20 more
openaire   +3 more sources

CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease

Biologicals, 2016
The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum ...
Kornelius, Schulze, Nadine, Koppka, Frederik, Lutter, Gunnar, Brandhorst, Stefan, Schreiber, Ulf, Helwig   +5 more
openaire   +2 more sources

CT-P13 in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology, 2017
The first biosimilar infliximab, CT-P13 infliximab-dyyb was approved in 2013 by the European Medicines Agency (EMA) and in 2016 by the United States Food and Drug Administration (FDA) and has been used for the treatment of rheumatoid arthritis (RA) for 4 years.
openaire   +2 more sources

A Review of CT-P13: An Infliximab Biosimilar

BioDrugs, 2014
CT-P13 (Remsima™; Inflectra™), a biosimilar of reference infliximab (Remicade(®)), is approved by the European Medicines Agency for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire   +2 more sources

Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

International Journal of Colorectal Disease, 2020
In this study, we evaluate the efficacy and safety of the biosimilar infliximab, CT-P13, in the treatment of inpatients with severe steroid-refractory colitis.A retrospective cohort study of adult colitis patients (UC or isolated Crohn's colitis) admitted to the University of Chicago inflammatory bowel disease inpatient service between January 2018 and
Jacob E. Ollech, Inessa Normatov, Noam Peleg, Sushila R. Dalal, Joel Pekow, Dejan Micic, Russel D. Cohen, David T. Rubin, Atsushi Sakuraba   +8 more
openaire   +2 more sources

Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU

Clinical Drug Investigation, 2021
CT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after ...
openaire   +2 more sources

Ineffectiveness of infliximab CT‐P13 for the treatment of scleromyxedema: A case report

Dermatologic Therapy, 2017
a
Arginelli, Federica, Paganelli, Alessia, Rongioletti, Franco, Pellacani, Giovanni, Conti, Andrea   +4 more
openaire   +2 more sources

A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases

Expert Review of Clinical Immunology, 2015
The development of biologic drugs has undoubtedly enhanced the spectrum of treatments available for immune-mediated inflammatory rheumatic diseases such as rheumatoid arthritis. However, despite their clear clinical benifits, use of biologics is often hindered by their high costs.
openaire   +2 more sources